XNAS
CVKD
Market cap29mUSD
May 13, Last price
14.79USD
1D
10.54%
1Q
-23.68%
IPO
-74.85%
Name
Cadrenal Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
0k
P
CFO
-7m
L+108.41%
Profile
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY |
|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | |
| Income | |||
Revenues | |||
Cost of revenue | 10,959 | 7,633 | 394 |
Unusual Expense (Income) | |||
NOPBT | (10,959) | (7,633) | (394) |
NOPBT Margin | |||
Operating Taxes | 4 | ||
Tax Rate | |||
NOPAT | (10,959) | (7,633) | (394) |
Net income | (8,357) 24.47% | (6,714) | |
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | 5,144 | 11,903 | 1,240 |
BB yield | -29.11% | -123.54% | |
| Debt | |||
Debt current | 43 | 66 | |
Long-term debt | 21 | 618 | |
Deferred revenue | |||
Other long-term liabilities | 4,420 | ||
Net debt | (10,018) | (8,338) | 652 |
| Cash flow | |||
Cash from operating activities | (7,358) | (3,530) | (1,205) |
CAPEX | (3) | ||
Cash from investing activities | (7) | (3) | (2) |
Cash from financing activities | 8,980 | 11,903 | 1,240 |
FCF | (10,942) | (8,152) | |
| Balance | |||
Cash | 10,018 | 8,402 | 33 |
Long term investments | |||
Excess cash | 10,018 | 8,402 | 33 |
Stockholders' equity | (25,721) | (15,058) | (6,706) |
Invested Capital | 33,161 | 22,793 | 6,216 |
ROIC | |||
ROCE | 80.39% | ||
| EV | |||
Common stock shares outstanding | 1,220 | 868 | 776 |
Price | 14.49 30.56% | 11.10 | |
Market cap | 17,671 83.40% | 9,636 | |
EV | 7,653 | 1,297 | |
EBITDA | (10,957) | (7,631) | (393) |
EV/EBITDA | |||
Interest | 17 | 107 | |
Interest/NOPBT | |||